Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 3/20 | 0.59 |
| ▸ | ERCC4 | Q92889 | 3/20 | 0.59 |
| ▸ | F2 | P00734 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108111 | 0.84 | HTT (0.50) | ALDH1A1USP2 | |
| SCHEMBL6221764 | 0.83 | KDM4E (0.49) | ALDH1A1POLB | |
| SCHEMBL6221760 | 0.83 | KDM4E (0.49) | ALDH1A1POLB | |
| SCHEMBL107960 | 0.81 | ERCC1 (0.60) | ERCC1ERCC4F2ALDH1A1PKM | |
| SCHEMBL145365 | 0.81 | ERCC1 (0.60) | ERCC1ERCC4F2ALDH1A1PKM | |
| SCHEMBL21696537 | 0.79 | F2 (0.50) | ERCC1ERCC4F2ALDH1A1PKM | |
| SCHEMBL12509105 | 0.78 | ERCC1 (0.55) | ERCC1ERCC4F2ALDH1A1PKM | |
| SCHEMBL11761768 | 0.78 | ALPG (0.55) | ERCC1ERCC4F2ALDH1A1CYP3A4 | |
| SCHEMBL21696657 | 0.78 | PKM (0.54) | F2ALDH1A1PKMCYP3A4CYP2C9 | |
| SCHEMBL12421634 | 0.78 | ERCC1 (0.55) | ERCC1ERCC4F2ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163957-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease | PROTEOTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163957-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease | PROTEOTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090197965-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | SNOW ALAN D | 2009-08-06 | — | — | US | disclosed |
| US-20090197965-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | SNOW ALAN D | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197965-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | IAPP, APP, SNCA | ERCC1 4117/4885ERCC4 4337/4885F2 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.